1. Home
  2. ETNB vs KALU Comparison

ETNB vs KALU Comparison

Compare ETNB & KALU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ETNB
  • KALU
  • Stock Information
  • Founded
  • ETNB 2018
  • KALU 1946
  • Country
  • ETNB United States
  • KALU United States
  • Employees
  • ETNB N/A
  • KALU N/A
  • Industry
  • ETNB Biotechnology: Pharmaceutical Preparations
  • KALU Metal Fabrications
  • Sector
  • ETNB Health Care
  • KALU Industrials
  • Exchange
  • ETNB Nasdaq
  • KALU Nasdaq
  • Market Cap
  • ETNB 1.2B
  • KALU 1.1B
  • IPO Year
  • ETNB 2019
  • KALU 1991
  • Fundamental
  • Price
  • ETNB $7.34
  • KALU $60.62
  • Analyst Decision
  • ETNB Strong Buy
  • KALU Buy
  • Analyst Count
  • ETNB 10
  • KALU 2
  • Target Price
  • ETNB $27.56
  • KALU $90.00
  • AVG Volume (30 Days)
  • ETNB 2.1M
  • KALU 122.3K
  • Earning Date
  • ETNB 05-08-2025
  • KALU 04-23-2025
  • Dividend Yield
  • ETNB N/A
  • KALU 5.05%
  • EPS Growth
  • ETNB N/A
  • KALU N/A
  • EPS
  • ETNB N/A
  • KALU 2.87
  • Revenue
  • ETNB N/A
  • KALU $3,024,000,000.00
  • Revenue This Year
  • ETNB N/A
  • KALU $10.02
  • Revenue Next Year
  • ETNB N/A
  • KALU $8.00
  • P/E Ratio
  • ETNB N/A
  • KALU $20.85
  • Revenue Growth
  • ETNB N/A
  • KALU N/A
  • 52 Week Low
  • ETNB $5.99
  • KALU $58.84
  • 52 Week High
  • ETNB $11.84
  • KALU $102.42
  • Technical
  • Relative Strength Index (RSI)
  • ETNB 39.62
  • KALU 29.16
  • Support Level
  • ETNB $7.66
  • KALU $66.14
  • Resistance Level
  • ETNB $9.32
  • KALU $68.80
  • Average True Range (ATR)
  • ETNB 0.77
  • KALU 2.14
  • MACD
  • ETNB -0.04
  • KALU -0.72
  • Stochastic Oscillator
  • ETNB 9.04
  • KALU 13.86

About ETNB 89bio Inc.

89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).

About KALU Kaiser Aluminum Corporation

Kaiser Aluminum Corp produces and sells semi-fabricated specialty aluminum products predominantly to industrial customers. Its products include fabricated aluminum mill products such as flat-rolled (plate, sheet, and coil), extruded (rod, bar, hollows, and shapes), drawn (rod, bar, pipe, tube and wire) and certain cast aluminum products. Geographically, the company generates majority of its revenue from United States.

Share on Social Networks: